Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant, M, Pfeiler, G, Dubsky, PC, Hubalek, M, Greil, R, Jakesz, R, Wette, V, Balic, M, Haslbauer, F, Melbinger, E, Bjelic-Radisic, V, Artner-Matuschek, S, Fitzal, F, Marth, C, Sevelda, P, Mlineritsch, B, Steger, GG, Manfreda, D, Exner, R, Egle, D, Bergh, J, Kainberger, F, Talbot, S, Warner, D, Fesl, C, Singer, CF. LANCET. 2015, 386(9992): 433-443.

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R. Br J Haematol. 2015 Aug,170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

AIDing cancer treatment: Reducing AID activity via HSP90 inhibition.

Rebhandl, S, Geisberger, R. Eur J Immunol. 2015, 45(8): 2208-2211.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant, M, Sestak, I, Filipits, M, Dowsett, M, Balic, M, Lopez-Knowles, E, Greil, R, Dubsky, P, Stoeger, H, Rudas, M, Jakesz, R, Ferree, S, Cowens, JW, Nielsen, T, Schaper, C, Fesl, C, Cuzick, J. ANN ONCOL. 2015, 26(8): 1685-1691.

Digging deep into „dirty“ drugs – modulation of the methylation machinery.

Pleyer, L, Greil, R. Drug Metab Rev. 2015, 47(2): 252-279.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, Mikušková, E, Gercheva, L, Nösslinger, T, Papajík, T, Ladická, M, Girschikofsky, M, Hrubiško, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, Stehlíková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7): e317-e329.

Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations.

Steiner, M, Harrer, A, Himly, M. Front Pharmacol. 2016, 7: 171.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2,5) translocation.

Merkel, O, Hamacher, F, Griessl, R, Grabner, L, Schiefer, AI, Prutsch, N, Baer, C, Egger, G, Schlederer, M, Krenn, PW, Hartmann, TN, Simonitsch-Klupp, I, Plass, C, Staber, PB, Moriggl, R, Turner, SD, Greil, R, Kenner, L. J Pathol. 2015, 236(4): 44-56.

[Therapie des Patienten mit Radioiod-refraktärem, differenziertem Schilddrüsenkarzinom. Ein Konsensusstatement].

Lindner, C, Dierneder, J, Pall, G, Pirich, C, Hoffmann, M, Raderer, M, Becherer, A, Niederle, B, Lipp, R, Lind, P, Gallowitsch, H, Romeder, F, Virgolini, I. Nuklearmedizin. 2015, 54(3): 125-130.

IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer-Results of a case series after 5-year follow-up.

Fastner, G, Reitsamer, R, Ziegler, I, Zehentmayr, F, Fussl, C, Kopp, P, Peintinger, F, Greil, R, Fischer, T, Deutschmann, H, Sedlmayer, F. Int J Cancer. 2015, 136(5): 1193-1201.